NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, February 7-8, in New York, NY, Raymond James & Associates' 45th Annual Institutional Investors Conference, March 4-6, in Orlando, Florida, and Leerink Partners Global ...

NEWARK, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to two employees on January 12, 2024 (the "Grant Date") in connection with the employees' commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock optio ...

Company Participants Paul Quinlan - General Counsel Chuck McWherter - Chief Scientific Officer & President of R&D Harish Shantharam - Chief Financial Officer Steven Seedhouse - Raymond James Cory Jubinville - LifeSci Capital Andy Hsieh - William Blair Operator Now, I would like to turn the call over to Mr. Paul Quinlan, General Counsel at CymaBay. Mr. Quinlan, please proceed. Thank you, operator and good afternoon everyone. I hope that you have had a chance to review the press release we issued announcing o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO (510) 293-8800 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check ...

Paul Quinlan - General Counsel Sujal Shah - President and Chief Executive Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Kristen Kluska - Cantor Fitzgerald Thomas Smith - Leerink Partners Operator Now, I would like to turn the call over to Mr. Paul Quinlan, General Counsel at CymaBay. Mr. Quinlan, please proceed. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Harish Shantharam - Chief Financial Officer Charles Mc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | |----------------------------------------------------------------------------------------|-----------------------------| | C ...

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Sujal Shah - President and Chief Executive Officer Lewis Stuart - Chief Commercial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Julian Harrison - BTIG Jay Olson - Oppenheimer Operator At this time, I would like to turn the call over to Mr. Paul Quinlan, General Counsel at CymaBay. Mr. Quinlan, please proceed. Joining me on the call today are Sujal Shah, Chief Exec ...

Total project costs decreased $2.3 million to $9.3 million from $11.6 million for the three months ended March 31, 2023 and 2022, respectively. The decrease was mostly due to the completion of enrollment of our RESPONSE trial and lower spending in drug manufacturing and development for PBC during the three months ended March 31, 2023. Project costs for the three months ended March 31, 2023 and 2022 primarily consisted of seladelpar-related clinical trial expenses for PBC. Internal research and development c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36500 CYMABAY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3103561 (State or other jurisdiction of (I.R.S. Employer incorporation or org ...

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Â Company Participants Paul Quinlan - General Counsel Sujal Shah - Chief Executive Officer Chuck McWherter - President, Research & Development and Chief Scientific Officer Lewis Stuart - Chief Commercial Officer Dan Menold - Vice President, Finance Conference Call Participants Yasmeen Rahimi - Piper Sandler Steven Seedhouse - Raymond James Kristen Kluska - Cantor Fitzgerald Ed Arce - H.C. Wainwright Jay Olson ...